bioihbjkbjnl/mcl2 huggingface dataset:
The Influence of Age and Gender on Tongue Pressure and Swallowing Tongue Pressure
Condition: Swallowing Disorder
MeSH terms: Deglutition Disorders
Study type: Observational

Summary: 
      The main topic of the research is to investigate the tongue's strength when swallowing. There
      has been much foreign literature on tongue strength. Iowa Oral Performance Instrument also
      has norms for reference, but the data are all taken from non-Asian people such as Caucasians.
      In this case, the credibility of the norms are decreased in domestic, and we also lack norm
      data of tongue strength when swallowing. Through the research, we can establish normative
      data belonging to the domestics, provide usable data for domestic researchers and clinical
      staff, and explore whether there are differences in age and gender in data between Taiwanese
      and foreigners.
    

Detailed description: 
      Swallowing refers to the process by which food enters the stomach from the mouth. It is the
      physiological mechanism by which humans take in water and nutrients. It is a vital activity
      for individual survival. The physiological mechanism of swallowing has four major stages,
      oral preparation, oral cavity, pharynx, and esophagus. Each stage has its physiological
      mechanism, which depends on the different nerve and muscle structures. In the oral stage, our
      tongue plays an important role. Whether in the formation or transition of the food bolus, it
      must rely on the tongue to perform its normal functions. The main topic of the research is to
      explore the strength of the tongue when swallowing. The purpose is to discuss the influence
      of gender and age on swallowing tongue pressure. We expect to recruit 80 subjects and divide
      them into three groups according to their age: 20 to 39 years old, 40 to 59 years old, and 60
      to 79 years old, with 13 to 14 males and females in each group, using Iowa Oral Performance
      Instrument measures the subject's maximum tongue pressure, average swallowing tongue
      pressure, and the ratio of the maximum tongue pressure used when swallowing, to explore
      whether age and gender affect tongue strength when swallowing.
    

Intervention name(s): Iowa Oral Performance Instrument
Intervention type(s): Behavioral
Intervention description(s): Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure
Observational model: Other
Time perspective: Cross-Sectional
Sampling method: Non-Probability Sample
Study population: 
        Healthy adult.
      
Keywords: Swallowing function; Age; Gender
Comparison Among Propofol, Alfentanil and Rocuronium as Adjunct to Sevoflurane Anesthesia for Endotracheal Intubation in Children With Frenectomy
Condition: Ankyloglossia
MeSH terms: Ankyloglossia
Study type: Interventional

Summary: 
      Several methods have been demonstrated to improve intubating conditions during sevoflurane
      induction in children. These include opioids, propofol, and addition of neuromuscular
      blocking agents in pediatric patients. But the study about the comparison of these agents has
      been uncommon. Frenectomy is common procedure to treat ankyloglossia. It is a short procedure
      performed under general anesthesia. The investigators aimed to compare intubating conditions
      among children with propofol, alfentanil or rocuronium after sevoflurane induction.
    


Intervention name(s): administration of propofol; administration of alfentanil; administration of rocuronium
Intervention type(s): Drug; Drug; Drug
Intervention description(s): intravenous administration of propofol 2 mg/kg before intubation; intravenous administration of alfentanil 14 μg/kg before intubation; Intravenous administration of rocuronium 0.3 mg/kg before intubation
Intervention MeSH terms: Alfentanil; Propofol; Rocuronium
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Care Provider, Investigator)
Primary purpose: Other
A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Condition: Diabetes Mellitus Type 2
MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 2
Study type: Interventional
Phase: Phase 2

Summary: 
      This 4 arm study will evaluate the tolerability, efficacy and pharmacodynamics of different
      doses of a GLP-1 analogue in patients with type 2 diabetes who are treated with a stable dose
      of metformin. Patients will be randomized to receive either subcutaneous placebo, or
      subcutaneous GLP-1 analogue (at a dose of 20mg, or a starting dose of 20mg escalating to
      either 30mg or 40mg), weekly. All patients will continue on their existing metformin
      treatment regimen throughout the study. The anticipated time on study treatment is <3 months,
      and the target sample size is 100-500 individuals.
    


Intervention name(s): Placebo; Taspoglutide 20mg; Taspoglutide 20mg-30mg; Taspoglutide 20mg-40mg
Intervention type(s): Drug; Drug; Drug; Drug
Intervention description(s): sc weekly; sc weekly; sc weekly; sc weekly
Intervention MeSH terms: Glucagon-Like Peptide 1
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD
Condition: Hyperphosphatemia
MeSH terms: Hyperphosphatemia
Study type: Interventional
Phase: Phase 2

Summary: 
      To evaluate the effect and safety of a switch from phosphate binders to KHK7791 to treat
      Hyperphosphatemia in patients on HD.
    


Intervention name(s): KHK7791
Intervention type(s): Drug
Intervention description(s): KHK7791 30 mg, 20 mg ,10 mg or 5 mg tablets
Other intervention name(s): Tenapanor
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Tenapanor; Hyperphosphatemia; Hemodialysis
Dose Escalation of Desmoteplase in Acute Ischemic Stroke (DEDAS)
Condition: Stroke
MeSH terms: Stroke; Ischemic Stroke
Study type: Interventional
Phase: Phase 1/Phase 2

Summary: 
      The purpose of this study was to explore trends in safety and efficacy, and to find the
      optimal dose for the subsequent phase III trial. The decision to initiate the phase III trial
      will depend on both safety (incidence of symptomatic intracranial hemorrhage) and efficacy
      (reperfusion measured by MRI and correlating with clinical outcome) profiles. The safety
      (incidence of symptomatic intracranial haemorrhage) and efficacy (reperfusion measured by MRI
      and correlating with clinical outcome) profiles gained from this study were the basis of
      planning the phase III.
    

Detailed description: 
      Acute stroke is the third leading cause of mortality in developed countries and the major
      medical cause of disability in adults. The outcome can be improved by early treatment with
      thrombolysis. Alteplase (r-tPA) is the only approved thrombolytic drug in the indication of
      acute ischemic stroke. However, the use of alteplase is currently restricted by the need to
      administer it within 3 hours of symptom onset. As the risk of transforming a cerebral infarct
      into haemorrhage probably rises as the time elapsed increases, a thrombolytic drug that
      carries a lower risk of haemorrhage than alteplase may offer a wider time-to-treatment window
      and improve the safety profile.

      Desmoteplase (DSPA) with its high fibrin specificity, lack of neurotoxicity, potential
      neuroprotective effect, non-activation by ß-amyloid, and long terminal half-life may account
      for an improved safety and efficacy profile within the first 9 hours after onset of symptoms.
    

Intervention name(s): Desmoteplase; Desmoteplase; Placebo
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Desmoteplase 90µg/kg BW i.v. bolus; Desmoteplase 125 µg/kg BW i.v. bolus; Placebo i.v. bolus
Intervention MeSH terms: Salivary plasminogen activator alpha 1, Desmodus rotundus
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Treatment
Keywords: Acute ischemic stroke
Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection
Condition: Malaria, Falciparum; Malaria, Vivax
MeSH terms: Malaria; Malaria, Falciparum; Malaria, Vivax
Study type: Interventional
Phase: Phase 2

Summary: 
      A Phase IIa Exploratory, Open label, Single Dose Regimen, Multiple Dose Testing Clinical
      Study to Assess the Preliminary Efficacy, Tolerability and Pharmacokinetics of OZ439 in adult
      patients with acute, uncomplicated Plasmodium falciparum or vivax malaria mono-infection.
    

Detailed description: 
      This exploratory Phase IIa study aims to investigate the preliminary efficacy in terms of
      parasite reduction and clearance in malaria patients, and the tolerability of OZ439
      administered as single dose regimen at 3 different doses in parallel cohorts of patients with
      either acute uncomplicated Plasmodium falciparum or Plasmodium vivax malaria mono-infection
      (10 patients per plasmodium species per dose level).

      Treatment with OZ439 will be given as a single dose on Day 0, starting in the first cohort at
      a dose of 800 mg. Established antimalarial therapy will be given at the latest at 36 hours
      post dosing.

      The primary endpoint will be the derived parasite reduction rate (PRR) at 24 hours after
      study drug administration.

      A review of each individual study cohort (dose/species) will be conducted with the Principal
      Investigator and the Sponsor and a decision will be reached on whether the dose for the next
      cohort should increase or decrease (within 200mg-1600mg range). This decision will be based
      on parasite reduction rate over the first 24 hours following administration of OZ439,
      tolerability and exposure.
    

Intervention name(s): OZ439
Intervention type(s): Drug
Intervention description(s): po, single dose
Other intervention name(s): Artefenomel
Intervention MeSH terms: Artefenomel
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Acute uncomplicated Plasmodium Falciparum malaria; Blood stage Plasmodium Vivax malaria
Immediate-Release Oxycodone Capsules Study in Cancer Pain
Condition: Cancer
MeSH terms: Cancer Pain
Study type: Interventional
Phase: Phase 3

Summary: 
      The efficacy of dose titration of OxyNorm™(Oxycodone) immediate-release capsules versus
      morphine immediate-release tablets in the treatment of cancer pain.
    

Detailed description: 
      To compare the efficacy of dose titration of OxyNorm™(Oxycodone) immediate-release capsules
      versus morphine immediate-release tablets in the treatment of cancer pain.
    

Intervention name(s): Oxycodone; Morphine
Intervention type(s): Drug; Drug
Intervention description(s): dosage: 5mg, l0mg and 20mg dosage form: capsule frequency: every 6h, duration: 5-8 days; Morphine tablets 10mg and 20mg, oral every 4-6 hours
Other intervention name(s): No other name in this study; No other name
Intervention MeSH terms: Morphine; Oxycodone
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Cancer Pain
High-Frequency Repetitive Transcranial Magnetic Stimulation Assists In Smoking Cessation
Condition: Heavy Smoking
Study type: Interventional

Summary: 
      Cigarette smoking is a major public health problem causing significant morbidity and
      mortality. Yet, smoking cessation therapies are often ineffective at helping smokers break
      their addiction.

      The mesolimbic dopaminergic reward system plays a crucial role in mediating the reinforcing
      effects of nicotine. Recently, acute high frequency repetitive transcranial magnetic
      stimulation (rTMS) of frontal brain regions has been shown to efficiently modulate the
      mesolimbic dopamine systems in both animals and humans. For this reason, we investigated
      whether 10 high-frequency (10Hz) rTMS treatments over the left dorsolateral prefrontal cortex
      can help people to withdraw smoking in comparison to placebo rTMS.

      Smokers seeking to quit are recruited through newspaper advertisements. Participants were
      randomized to 10 days of either real or placebo high frequency rTMS.
    


Intervention name(s): Transcranial Magnetic Stimulation 10Hz; Magnetic stimulation using a special sham coil
Intervention type(s): Device; Device
Intervention description(s): 3. rTMS subjects will receive 20 trains of rTMS at a rate of 10 Hz for 6 seconds (1200 pulses/session). Pulses will be administered over the left dorsolateral prefrontal cortex, defined as 5 cm anterior and in a parasagital plane to the point of maximum stimulation of the abductor pollicis muscle. Pulse intensity will be set at 100% motor threshold.; Sham stimulation will be given at the same location as the active, with special sham coil.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Primary purpose: Treatment
Keywords: rTMS, smoking, dopamine, acotinine
The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor
Condition: Solid Tumors
MeSH terms: Neoplasms
Study type: Interventional
Phase: Phase 1

Summary: 
      This study will evaluate the safety, tolerability, pharmacokinetics, food effect, and
      preliminary antitumor activities of BGB-283 in Chinese subjects with local advanced or
      metastatic malignant solid tumor.
    

Detailed description: 
      "This study is conducted on the basis of the completed multi-dose, dose escalation, Phase IA
      trial in Australia, is a dose-finding, dose expansion and food effects study of BGB-283
      capsules in Chinese patients with locally advanced or metastatic solid tumor to determine the
      tolerability, safety, pharmacokinetic profiles, preliminary efficacy, food effects under
      high-fat meal on the absorption and metabolism of BGB-283, and preliminary anti-tumor
      efficacy.

      The study was conducted in three phases: Stage I for dose escalation, Stage II for dose
      expansion and Stage III for food effects on pharmacokinetics under high fat meal.

      Stage I Dose escalation: In a open-label, dose-escalation design, dose escalation will be
      performed with the '3 + 3' scheme and the dosage levels of BGB-283 capsules will be gradually
      increased.

      Stage II Dose expansion: 20 mg/qd and 30 mg/qd are considered as effective and safe doses,
      based on preliminary results from Phase IA clinical studies in Australia. To further
      understand the preliminary pharmacodynamic results of BGB-283 in Chinese patients with
      malignant melanoma, 20mg/qd dose expansion study in B-RAF mutated malignant melanoma will be
      further explored if it has been proved to be a safe dose in Chinese population according to
      the '3 + 3' scheme.

      Stage III uses multi-center, open, two-group crossover self-control design to compare the
      high-fat meal effect on pharmacokinetics."
    

Intervention name(s): BGB-283
Intervention type(s): Drug
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Dose Escalation; Dose Expansion; BGB-283
Risk Analysis of Intensive Care Mangement on Maternal and Fetal Outcome of Severe Preeclampsia and Eclampsia
Condition: Hypertensive Disorder of Pregnancy
MeSH terms: Toxemia; Pre-Eclampsia; Eclampsia; Hypertension
Study type: Observational

Summary: 
      Laboratory monitoring of patients included serial measurement of complete blood cell count,
      liver function tests, coagulation profile, and renal function tests.

      ICU management during conduction of the research study included the following:

      Control of convulsions using magensium sulphate. Control of blood pressure Diastolic blood
      pressure above 110 mmHg, nifedipine was administered.A plasma volume expansion with saline
      was used in all women to maintain sufficient intravascular volume. Delivery was performed
      immediately after hemodynamic stabilization and clinical control of general condition .
    

Detailed description: 
      Laboratory monitoring of patients included serial measurement of complete blood cell count,
      liver function tests, coagulation profile, and renal function tests.

      ICU management included the following:

      Control of convulsions by Loading dose of magensium sulphate (4-6g I.V), given over 20
      minutes in 100 ml of dextrose then Maintenance dose (4-6g) magensium sulphate in 500 cc
      dextrose given over 8 hours using continuous IV drip.Control of blood pressure if Diastolic
      blood pressure above 110 mmHg, nifedipine was administered. Delivery was performed
      immediately after hemodynamic stabilization and clinical control of general condition
      .Termination of gestation decision was based on the the presence of maternal complications,
      fetal distress.After delivery the patient is retrurned to ICU under clinical and careful
      observation of the following:Heart rate, blood pressure,every 15 min,Temperature and
      respiratory rate ,evey 4 hours. Duration of admission in the ICU was assessed
    

Intervention name(s): MgSO4
Intervention type(s): Drug
Intervention description(s): Loading dose of magensium sulphate (4-6g I.V), given over 20 minutes in 100 ml of dextrose, Maintenance dose (4-6g) magensium sulphate in 500 cc dextrose given over 8 hours using continuous IV drip
Other intervention name(s): magnesium Sulfate
Intervention MeSH terms: Magnesium Sulfate
Observational model: Cohort
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Patients were diagnosed as severe preeclampsia if met one or more of the American College
        of Obstetricians and Gynecologists Eclampsia was defined as tonic-clonic seizures occurring
        in patient diagnosed by preeclampsia patient. .HELLP syndrome was defined by the clinical
        presentation of PET in association with thrombocytopenia (<150.000 cells/ul), hemolysis and
        elevated liver enzmes (elevated transaminases and lactic dyhydrogenases activities).
Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)
Condition: Hay Fever; Seasonal Allergic Rhinitis
MeSH terms: Rhinitis; Rhinitis, Allergic; Rhinitis, Allergic, Seasonal
Study type: Interventional
Phase: Phase 3

Summary: 
      The aim of the study is to determine the efficacy and safety of ciclesonide nasal spray in
      children with seasonal allergic rhinitis. Ciclesonide will be administered intranasally at
      two dose levels once daily. The study consists of a baseline period (1 to 3 weeks) and a
      treatment period (2 weeks).
    


Intervention name(s): Ciclesonide nasal spray
Intervention type(s): Drug
Intervention MeSH terms: Ciclesonide
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double
Primary purpose: Treatment
Keywords: Hay Fever; Seasonal Allergic Rhinitis; Nasal spray; Ciclesonide; Allergic Rhinitis
The Effect of Turmeric on New Onset Primary Dysmenorrhea
Condition: Primary Dysmenorrhea
MeSH terms: Dysmenorrhea
Study type: Interventional

Summary: 
      The study was planned as 150 patients. Patients who met early-onset dysmenorrhea criteria and
      who met the inclusion criteria; 150 patients were divided into 2 equal groups, and NSAID
      during the menstrual cycle, nsai + turmeric 1 gr oral powder form treatment was planned to be
      started in the other group. The pain frequency and severity before and after treatment were
      evaluated by visual analog scale and the two groups were compared.
    

Detailed description: 
      There are scientific publications on the use of turmeric, which constitutes the hypothesis of
      our study, in branches such as cardiology, neurology, infertility and chest diseases due to
      its anti-inflammatory, anti-aging properties.

      The data are planned to be evaluated by the researchers using the SPSS(Statistical Package
      for the Social Sciences ) 17.0 program on computer. The responses of all groups to the VAS
      scores are planned to be entered into the system by using the SPSS program before and after
      treatment. statistics (number, percentage, mean, standard deviation), chi-square and logistic
      regression analysis are used to compare categorical variables. Chi-square test and Mann
      Whitney-U test are planned to be used in comparison between groups.When examining the
      difference between the groups, if the p value is less than 0.05, it is planned as a proof of
      significant difference.
    

Intervention name(s): Naproxen; Turmeric
Intervention type(s): Drug; Dietary Supplement
Intervention description(s): use of naproxen twice a day orally in mens time; Use of turmeric orally (1 gram powder formula) in mens time
Other intervention name(s): NSAI(nonsteroidal anti-inflammatory agent)
Intervention MeSH terms: Naproxen; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: new onset primary dysmenorrhea; turmeric; naproxen